Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.

Original publication

DOI

10.1136/bmj.284.6322.1081

Type

Journal article

Journal

Br Med J (Clin Res Ed)

Publication Date

10/04/1982

Volume

284

Pages

1081 - 1084

Keywords

Adolescent, Adult, Child, Child, Preschool, Clinical Trials as Topic, Deferoxamine, Dose-Response Relationship, Drug, Humans, Life Expectancy, Random Allocation, Thalassemia